M
ost, but not all, second-generation antipsychotic drugs have been reported to have fewer motor side effects than firstgeneration drugs but to be associated with increased risk of weight gain, diabetes, and high cholesterol. 1Y5 The recent Clinical Antipsychotic Trials of Intervention Effectiveness study 6 pointed out the need for an effective antipsychotic without either extrapyramidal symptoms (EPSs) or metabolic effects.
BL-1020 is a novel orally administered antipsychotic that is a gamma aminobutyric acid (GABA) ester of perphenazine. It is believed to be at least as effective and to have a better safety profile than perphenazine, which was found in the Clinical Antipsychotic Trials of Intervention Effectiveness study to be as efficacious and well tolerated as second-generation antipsychotics. 6 The theoretical rationale for the combination of GABA and perphenazine in treating psychosis, the pharmacological properties of BL-1020, and the results of animal studies have been presented elsewhere. 7, 8 Briefly, BL-1020 combines dopamine receptor blockade (high affinity for D 2L and D 2S ) with high affinity for serotonin 5-HT 2A and histamine H 1 receptors. However, unlike first-and second-generation antipsychotics, it has agonist activity at the GABA A receptor but no activity at the metabotropic GABA B receptor. 8 Studies implicate hypoactivity of GABA, a major inhibitory neurotransmitter in the human brain, in schizophrenia. 9Y14 Research suggests that increased GABA-ergic transmission may improve symptoms of schizophrenia and attenuate drug-induced EPS. 15 , 16 Pharmacokinetic studies demonstrate that BL-1020 enters the brain, increases dopamine release in the prefrontal cortex and hippocampus, and has the ability to reverse cognitive impairment induced by phencyclidine in animal behavioral models. In preclinical studies, BL-1020 has shown a very favorable safety profile, while retaining potent efficacy. In animal models, BL-1020 was devoid of cataleptic EPS-like side effects at doses associated with efficacy. 8 It is thus hypothesized that this combination of pharmacological actions will provide superior antipsychotic efficacy for BL-1020, with less EPS seen with firstgeneration antipsychotics, or the metabolic effects associated with atypical antipsychotics.
This was the first study to examine BL-1020 as an antipsychotic treatment and to examine dose response. The drug was developed by BioLineRx, a clinical-stage, publicly traded, biopharmaceutical development company based in Jerusalem, Israel, with US offices in Rockville, Md. The drug has completed a phase 2b clinical trial and is currently licensed in the United States to Cypress Pharmaceutical.
MATERIALS AND METHODS

Study Design
Study BL-1020-IIa was an open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of BL-1020 tri-mesylate (free base) in hospitalized patients with chronic schizophrenia or schizoaffective disorder.
As no previous safety or tolerability data were available for this target population, the study used measures to ensure patient safety, including mandatory hospitalization for the first 14 days of treatment. Initially, 2 cohorts were planned (cohort 1: 20Y40 mg/d; cohort 2: 30Y50 mg/d). However, the results of the first cohort, reported here, suggest that the maximum tolerated dose was reached, thus the second cohort was not recruited. The dose selection was based on nonclinical studies, animal models of efficacy and safety (catalepsy), and a positron emission tomography study done that showed that pharmacokineticY pharmacodynamic analysis predicted that oral once daily administration of 32 mg BL-1020 (20 mg free base) would result in D2 receptor occupancy ranging from 52% to 66% at a steady state. 8, 17 Patient Population
Patients included were male and female subjects (excluding those of childbearing potential), ages 18 to 65 years, inclusive, with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, diagnosis of chronic schizophrenia or schizoaffective disorder, with the diagnosis having been established at least 1 year before screening. Patients were required to be in need of antipsychotic treatment, which was operationalized as having the following: a Positive and Negative Syndrome Scale (PANSS) 18 total score of higher than 60, persistent positive symptoms while on current medication, or after having discontinued their medication; a PANSS score of 4 or higher on at least one of the following symptoms: conceptual disorganization, hallucinations, delusions, grandiosity, or suspiciousness; and a Clinical Global ImpressionYSeverity (CGI-S) 19 rating of 3 to 5 (Bmildly ill[ to Bmarkedly ill[). In addition, the current episode of schizophrenia or schizoaffective disorder must have been present and the patient symptomatic for at least 1 month.
The study was conducted according to the principles of Good Clinical Practice. 20 Approval was obtained from local institutional review boards, and patients provided written informed consent to participate in the study.
Procedures
Patients that provided written informed consent and met all entry criteria at the screening and baseline evaluations, which were conducted August to October 2007, were initiated at a dose of 20 mg given orally as capsules once daily and had their dose increased to 30 mg/d on day 4 and to 40 mg/d on day 7, provided the preceding dose was well tolerated. Patients could remain on their current dose or drop back to a lower dose if intolerance occurred. Safety and efficacy assessments were performed at weekly visits on days 7, 14, 21, 28, 35, and 42, with daily vital signs assessments being done during the initial 2-week dose titration period. The occurrence of any adverse events (AEs) and administration of concomitant medications were recorded throughout the study.
Patients were required to remain hospitalized during the initial 14 days of the study but could be treated as outpatients thereafter, based on their weekly rating on the Readiness for Discharge Questionnaire (RDQ) 21 and the judgment of the investigator. All end point evaluations were to be performed at Day 42 or at the time of early discontinuation. All patients were followed for 30 days after the last dose of study medication for the occurrence of any serious adverse events (SAEs).
Safety and Efficacy Measures
The tolerability and safety of BL-1020 was assessed based on incidence of adverse events (AEs), dropouts due to AEs, weekly Family or significant other, n = 25; inpatient, n = 5; alone, n = 3; other, n = 3 Inpatient status at time of entering study Outpatients, n = 30; inpatients, n = 6 Diagnostic distribution Schizophrenia, n = 33; schizoaffective disorder, n = 3 Onset of symptoms Gradual, n = 26; abrupt, n = 10 Duration of illness (mean yr) 13.5 (SD, 9. 0.4 (SD, 0.7) Common comorbidities Dyslipidemia, n = 2; insomnia, n = 2 Most common medications (910% of patients) Antipsychotics Haloperidol, n = 17; olanzapine, n = 14; levomepromazine, n = 9; amisulpride, n = 8; thioxanthine derivatives, n = 6; risperidone, n = 4; quetiapine, n = 4 Other psychotropics Benzodiazepines, n = 30; antidepressants, n = 9; anticholinergics, n = 11; valproic acid, n = 7; carbamazepine, n = 5 Others Pyridoxine, n = 4; glucose, n = 4; thiamine, n = 4 CGI-S, 19 and the CGI-Change (CGI-C). 19 A secondary efficacy measure was the RDQ, which yields a dichotomous BYes/No[ outcome regarding the suitability of the patient for being discharged from the hospital and treated as an outpatient.
Statistical Methodology
The safety and efficacy population consisted of all patients who had at least 1 dose of study medication. Comparisons for key efficacy variables were made between baseline and each time point (observed cases) or end point (last observation carried forward [LOCF]) using a paired samples t test. For other efficacy measures, descriptive statistics were provided for mean values and/or mean changes from baseline at end point, and the number and percentage of patients were provided for categorical variables. Table 1 presents the baseline characteristics of the 36 patients. Thirty-two (88.9%) of the 36 patients completed the 6-week trial. The reasons for premature discontinuation were AE (n = 1), withdrawal of consent (n = 1), failure to return for visit (n = 1), and exacerbation of symptoms (n = 1). Table 2 presents patient level data on efficacy and safety.
RESULTS
Patient Characteristics and Disposition
Tolerability of the Dose Titration
Doses were planned to be increased on days 4 and 7 based on tolerability and were to be maintained on days 14, 21, 28, and 35, except in the case of AEs that required a dose reduction. All patients were able to tolerate the starting dose of 20 mg/d. Only 1 patient did not have their dose increased to 30 mg/d on day 4 because of the occurrence of parkinsonism. On day 7, 30 of 35 patients had their daily dose increased from 30 to 40 mg. The following numbers of patients were receiving each of the dose levels at end point: 20 mgV2 (5.6%; 1 discontinuation); 30 mgV 2 (5.6%); and 40 mgV32 (88.9%; 3 discontinuations). Table 3 presents treatment-emergent AEs and concomitant medications taken during the study. It shows that 24 patients had at least 1 AE, with 20 patients having an AE judged by the investigator to be related to the study medication. Only 1 patient had a serious AE, and only 1 patient discontinued treatment because of an AE. The most commonly reported AE was insomnia, which occurred in 6 patients. All AEs were of either mild or moderate severity, except for a single report of severe akathisia. Only 10 of the patients required a nonpsychotropic medication. Half of the patients took at least 1 psychotropic medication during the treatment period; however, only 3 patients received additional antipsychotic medication. As shown in Table 4 , the mean changes from baseline on the ESRS total score were generally small (2 points or less), with both increases and decreases being observed.
Safety
There were no meaningful changes from baseline at any time point for systolic or diastolic blood pressure, pulse, or oral temperature. Small mean increases in body weight were noted from day 4 onward, with values increasing over time and a maximum mean weight gain of 0.8 T 1.14 kg being observed at the end point assessment; however, a large degree of variability in weight measurements was noted in some patients over the course of the study, suggesting possible artifactual causes. No clinically notable changes in any vital sign parameter, including body weight, were noted at any time in the study. No patient experienced a clinically significant treatment-emergent electrocardiogram (ECG) abnormality as judged by the central cardiologist. No clinically meaningful changes from baseline were noted in any of the ECG intervals, including QTc interval, which showed a small mean decrease (È2 milliseconds) at the end point visit.
The results for the laboratory tests (hematology, biochemistry and urinalysis) did not indicate any clinically meaningful pattern of adverse change, with only sporadic and infrequent clinically notable abnormalities being observed. Glucose levels (milligrams per deciliter) showed an increase of 4.3 T 17.53 from baseline of 80.2 T 8.00 (n = 33) to 85.5 T 19.11 at end of study (n = 33). The only parameter that showed a meaningful change was plasma prolactin (Table 3) , for which dose-dependent Moderate parkinsonism (started on day 4 at a dose of 20 mg/d, treated with anticholinergic therapy, led to discontinuation on day 7) Commonly reported Insomnia, n = 6; extrapyramidal disorder, n = 3; headache, n = 3; parkinsonism, n = 3; tremor, n = 3; hyperprolactinemia, n = 3; anxiety, n = 2; nausea, n = 2; somnolence; n = 2 Other important (all n = 1) Dizziness; dystonia; psychomotor hyperactivity Concomitant medications Psychotropic At least one, n = 18 Anxiety, agitation, and insomnia (n = 17)
Lorazepam, n = 7; diazepam, n = 6; zolpidem, n = 4 EPS (n = 10) Trihexyphenidyl, n = 10 Antipsychotic (n = 3) Quetiapine, n = 1; ziprasidone, n = 1; levomepromazine, n = 1 Mood stabilizer (n = 1) Carbamazepine, n = 1 Non-psychotropic (n = 10) Paracetamol, n = 4; ambazone, n = 2; ascorbic acid, n = 2; metamizole sodium, n = 2 increases in mean values were noted, in particular in the samples taken 4 hours postdose on the initial day of dosing (day 1) and on days of dose increases (days 4 and 7). On the CGI-S at end point, only 2 patients were rated as Bmarkedly ill[ as compared with 10 at baseline. In addition, 9 patients were considered Bborderline ill[ and 17 Bmildly ill[, whereas no patients were rated in these categories at the baseline evaluation. As shown in Table 5 , there were improvements from baseline at each postbaseline visit on the PANSS total score (P G 0.001) and CGI-S (P G 0.003), with mean changes to end point as follows: PANSS, j21.8 (SD, 15.81), and CGI-S, j1.2 (SD, 0.92). The mean CGI-C rating at end point was 1.7 (SD, 1.28; P G 0.001) corresponding to a rating between Bminimally[ and Bmuch improved[. The proportion of patients rated by the investigator as being ready for discharge from the hospital on the RDQ increased from 34.3% (12 of 35) at the end of the dose titration period (day 14) to 70.6% (24 of 34) on day 42. As per the study protocol, patients who had a rating of BYes[ on the RDQ, and who had an appropriate caregiver, could be discharged from the hospital on day 14 and treated as outpatients. As a result, 8 of the 12 patients who were rated as Bready for discharge[ at day 14 were released from the hospital and treated as outpatients for the remainder of the study.
DISCUSSION
This was the first study to assess BL-1020 in treating schizophrenia. There was no clinically relevant increase in body weight, sedation, dizziness, or other central nervous system effects or ECG/laboratory abnormalities. The apparent increased risk of motor symptoms may be attributable to the high starting dose, rapid titration, and the very high doses administered. We note that one third of the sample were given anticholinergic medication to Although this was an open-label trial not intended to demonstrate efficacy, the low dropout rate and the improvements on all efficacy parameters strongly suggest that BL-1020 is an effective drug. However, this will have to be demonstrated in larger, blinded, placebo-controlled trials.
